EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Cinclus Pharma secured funding to support its preparations for a phase 2 trial of a potassium competitive acid blocker in erosive gastroesophageal reflux disease. Statement 

> Mereo BioPharma completed its reverse merger with OncoMed Pharmaceuticals and began trading on Nasdaq. The developments extend Mereo’s cash runway out to the middle of next year. Release I More

> The FDA granted orphan drug status to Autolus Therapeutics’ CD19-CD22 cell therapy AUTO3 in the treatment of acute lymphoblastic leukemia. Statement 

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Marinomed Biotech posted top-line data from a phase 3 clinical trial of allergic rhinitis nasal spray Budesolv. The trial found Budesolv had comparable effects to another budesonide product but at a lower dose. Release 

> Cytura Therapeutics raised seed funding to develop drugs targeting genomic instability in cancer.  A syndicate led by Thuja Capital Healthcare put up the money. Statement 

> Oxurion completed enrollment in a phase 1 trial of plasma kallikrein inhibitor THR-149 ahead of schedule. The milestone positions Oxurion to share initial data on the diabetic macular edema prospect early in the third quarter. Release 

Suggested Articles

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.